Cell surface heparan sulfate proteoglycans control adhesion and invasion of breast carcinoma cells by unknown
Lim et al. Molecular Cancer  (2015) 14:15 
DOI 10.1186/s12943-014-0279-8RESEARCH Open AccessCell surface heparan sulfate proteoglycans control
adhesion and invasion of breast carcinoma cells
Hooi Ching Lim1,2, Hinke AB Multhaupt1 and John R Couchman1*Abstract
Background: Cell surface proteoglycans interact with numerous regulators of cell behavior through their
glycosaminoglycan chains. The syndecan family of transmembrane proteoglycans are virtually ubiquitous cell surface
receptors that are implicated in the progression of some tumors, including breast carcinoma. This may derive from
their regulation of cell adhesion, but roles for specific syndecans are unresolved.
Methods: The MDA-MB231 human breast carcinoma cell line was exposed to exogenous glycosaminoglycans and
changes in cell behavior monitored by western blotting, immunocytochemistry, invasion and collagen degradation
assays. Selected receptors including PAR-1 and syndecans were depleted by siRNA treatments to assess cell
morphology and behavior. Immunohistochemistry for syndecan-2 and its interacting partner, caveolin-2 was performed
on human breast tumor tissue arrays. Two-tailed paired t-test and one-way ANOVA with Tukey’s post-hoc test were
used in the analysis of data.
Results: MDA-MB231 cells were shown to be highly sensitive to exogenous heparan sulfate or heparin, promoting
increased spreading, focal adhesion and adherens junction formation with concomitantly reduced invasion and matrix
degradation. The molecular basis for this effect was revealed to have two components. First, thrombin inhibition
contributed to enhanced cell adhesion and reduced invasion. Second, a specific loss of cell surface syndecan-2 was
noted. The ensuing junction formation was dependent on syndecan-4, whose role in promoting actin cytoskeletal
organization is known. Syndecan-2 interacts with, and may regulate, caveolin-2. Depletion of either molecule had the
same adhesion-promoting influence, along with reduced invasion, confirming a role for this complex in maintaining
the invasive phenotype of mammary carcinoma cells. Finally, both syndecan-2 and caveolin-2 were upregulated
in tissue arrays from breast cancer patients compared to normal mammary tissue. Moreover their expression levels
were correlated in triple negative breast cancers.
Conclusion: Cell surface proteoglycans, notably syndecan-2, may be important regulators of breast carcinoma
progression through regulation of cytoskeleton, cell adhesion and invasion.
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Metastasis is a multistep process involving dissemination
of cancer cells from a primary tumour to distant organs
[1]. During metastasis from solid tumours, cells change
their adhesion status to facilitate migration through
basement membrane and extracellular matrix, enter the
bloodstream or lymphatics, extravasate into distant or-
gans and eventually proliferate to form metastases [2].* Correspondence: john.couchman@bric.ku.dk
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unless otherwise stated.Understanding the molecular basis of tumour cell motil-
ity and invasion is crucial to identify attractive targets
for potential therapeutic intervention.
In mammals, syndecans are a four-member family of
cell surface heparan sulfate proteoglycans that are well
placed to be important regulators of cell migration and
tumor progression. While expression of each syndecan
has some tissue- and cell type- specificity, they can bind
to a wide range of proteins including growth factors, cy-
tokines, chemokines, morphogens, extracellular matrix
proteins, proteinases and proteinase inhibitors through
their heparan sulfate chains [3,4]. Syndecans have anis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Lim et al. Molecular Cancer  (2015) 14:15 Page 2 of 18ability to regulate cell motility, cell-cell and cell-
extracellular matrix adhesion through signaling to the
actin cytoskeleton, with which all syndecans can interact
[5,6]. Additionally, the core protein of syndecans can
directly or indirectly promote integrin-mediated adhe-
sion and integrin turnover [7-11]. Although not posses-
sing intrinsic kinase activity, the syndecan proteoglycans
can nevertheless signal through their cytoplasmic do-
mains, mediated by specific binding partners, e.g. pro-
tein kinase Cα in the case of syndecan-4 [12-14].
In tumors, syndecan expression is frequently altered
during malignant transformation and may contribute to
tumor progression [15-18]. For example, syndecan-1 ex-
pression and its shedding from the cell surface appear to
relate directly to myeloma progression [15,19]. Syndecan-
4 may play differing roles in modulating tumor cell
invasiveness depending on the cancer type. In breast
carcinoma, syndecan-1 can promote cell spreading and
adhesion to extracellular matrix with subsequent inhib-
ition of cell invasion [20]. We showed that syndecan-4
expression in human breast carcinoma tissues corre-
lates with positive estrogen and progesterone receptor
status therefore a good prognosis [21]. Conversely,
syndecan-1 expression in breast carcinoma is an indica-
tor of poor prognosis, particularly where it is stromal
[21,22]. Syndecan-2 expression is upregulated in colon
cancer, pancreatic cancer, melanoma and fibrosarcoma
where it enhances cell adhesion, proliferation and migra-
tion in cancer cells, suggesting that it is important in
promoting tumor progression [23-26]. However, while
emerging evidence suggests that syndecans have prom-
inent regulatory roles in cancer cell behaviour, the mo-
lecular basis of these effects remains mostly obscure.
Here we show that cell surface heparan sulfate proteo-
glycans have multiple roles in governing invasive behav-
ior of the MDA-MB231 breast carcinoma cell line.
Specifically, a key role for a syndecan-2/caveolin-2 axis
is identified and characterized. Moreover, both of these




Human MDA-MB231 cells were grown in Dulbecco’s
modified Eagle’s Media from Life Technologies (Carlsbad,
CA, USA) containing 10% fetal bovine serum (FBS) at
37°C and 5% CO2. Cultures were screened routinely for
mycoplasma contamination.
Antibodies and reagents
The following antibodies were used: MMP14 (cat. no.
ab-3644) and syndecan-1 (clone B-A38) from Abcam
(Cambridge, UK); syndecan-2 (cat. no. H00006383-B04P)
from Abnova (Taiwan); syndecan-2 (cat. no. LSB2981) andsyndecan-4 (cat. no. LS-C150078) from LSBio (Seattle,
WA, USA); caveolin-2 (D4A6) (cat. no. 8522), cadherin-11
(P707) (cat. no. 4442), MLC (cat. no. 3672) and phospho-
MLC (Thr18/Ser19) (cat. no. 3674) from Cell Signaling
(Beverly, MA, USA); caveolin-1 (clone 2297, cat. no.
610406) and flotillin (cat. no. 610820) from BD Biosci-
ences (San Diego, CA, USA); p120-catenin (clone 6H11,
cat. no. 339700) and transferrin receptor (clone H68.4,
cat. no. 136800) from Life Technologies (Carlsbad, CA,
USA); paxillin (clone 5H11, cat. no. 05–417) from
Millipore (Billerica, MA, USA); β-tubulin (clone TUB2.1,
cat. no. T4026) from Sigma-Aldrich (St Louis, MO, USA);
Alexa Fluor-conjugated phalloidin and secondary anti-
bodies used in immunofluorescence analysis were ob-
tained from Life Technologies and peroxidase-conjugated
secondary antibodies used in all western blotting analysis
were purchased from Dako (Glostrup, Denmark).
The metalloproteinase inhibitor GM6001, DMSO, hepa-
ran sulfate from bovine kidney, chondroitin sulfate A from
bovine trachea, and heparin from bovine intestinal mu-
cosa were purchased from Sigma-Aldrich (St Louis, MO,
USA). ROCK inhibitor (Y-27632) was obtained from
Calbiochem (Darmstadt, Germany) and human anti-
thrombin III was purchased from Alpha Diagnostic Inter-
national (San Antonio, TX, USA).
siRNA and DNA transfections
Cells were transfected with siRNA targeting syndecan-1
(sc-36587, Santa Cruz Biotechnology, CA, USA),
syndecan-2 (sc-41045, Santa Cruz Biotechnology, CA,
USA), syndecan-4 (5′-ggccgauacuucuccggaguu-3′, Qiagen,
Frederick, MD, USA), MMP14 (5′-caggcaaagcugaugca-
gauu-3′, Qiagen), PAR-1 (5′-aaggcuacuaugccuacua-
cuuu-3′, Thermo Fisher Scientific, Waltham, MA,
USA), caveolin-1 (siGENOME SMARTpool, Thermo
Scientific), caveolin-2 (siGENOME SMARTpool, Thermo
Scientific) or non-targeting siRNA (siGENOME SMART-
pool, Thermo Scientific) using HiPerFect transfection
reagent (Qiagen) according to the manufacturer’s instruc-
tions. Cells were analyzed 48 h after transfection.
RNA isolation and quantitative reverse transcription-
polymerase chain reaction
Total RNA was isolated using the RNeasy Micro Kit
(Qiagen). Reverse transcription was performed with 1 μg
of RNA by using TaqMan reverse transcription kit (Life
Technologies) according to manufacturer’s protocol and
quantitative PCR was performed using the Maxima
SYBR Green qPCR Master Mix (Thermo Scientific) with
the following primers:
syndecan-1 (forward: 5′-tactaatttgccccctgaagat-3′, re-
verse: 5′-caaggtgatatcttgcaaagca-3′), syndecan-2 (forward:
5′-actgttgactagtgctgctcca-3′, reverse: 5′-gggtccattttcctttct
gagt-3′), syndecan-3 (forward: 5′-aagagtatcctggagcggaag-3′,
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ward: 5′-gtgtccaacaaggtgtcaatgt-3′, reverse: 5′-cggtacat
gagcagtaggatca-3′), PAR-1 (forward: 5′-acttgatcctggcca
cagac-3′, reverse: 5′-acttgatcctggccacagac-3′), RPLPO
(forward: 5′-ttcattgtgggagcagac-3′ reverse: 5′-cagcagttt
ctccagagc-3′).
Flow cytometry analysis
Cells were harvested with cell dissociation buffer (Life
Technologies), re-suspended in ice-cold sterile filtered
1% BSA/PBS and incubated at 4°C for 30 min in the
presence of syndecan-1 (1:50 dilution) syndecan-2 (1:100
dilution) or syndecan-4 (1:50 dilution) antibodies or
MMP14 (2 μg/ml) antibody. Cells were washed with ice-
cold sterile filtered 1% BSA/PBS and further incubated
with Alexa Fluor 488-conjugated secondary antibody for
30 min on ice. Following washing with ice-cold sterile
filtered 1% BSA/PBS, cells were analysed on a FACSCali-
bur flow cytometer and data processed by using Cell-
Quest Pro v6.0 software (Becton Dickinson, Franklin
Lakes, NJ, USA). Time course experiments were orga-
nized so that the harvesting and staining procedures
were synchronised.
Fluorescence microscopy
Cells were plated on glass coverslips in complete
medium (10% FBS) and after 24 h were then treated for
24 h with 20 μg/ml heparan sulfate, heparin or chondro-
itin sulfate, either in serum-free or serum-containing
medium. Control cultures were not treated with glycos-
aminoglycans. Cultures were fixed in 4% paraformalde-
hyde and permeabilized with 0.1% Triton X-100 in PBS.
After washing with PBS, free aldehydes were quenched
with 0.1 M ammonium chloride, followed by blocking in
5% heat-denatured BSA. Cells were incubated with Alexa
Fluor-conjugated phalloidin (1:1000) and/or primary
antibody recognising cadherin-11 (1:100), p120-catenin
(1:100) or paxillin (1:100) overnight at 4°C. After primary
incubation, cells were washed with PBS and incubated
with an appropriate fluorescent conjugated secondary
antibody (1:2000) for 1 h at room temperature. Coverslips
were mounted with ProLong antifade mounting medium
(Life Technologies) and analysed on a Zeiss Axioplan-2
microscope (Carl Zeiss, Oberkochen, Germany). Images
were processed using Metamorph (version 6.2r6) and
Adobe Photoshop (version 11.0.2). ImageJ (version 1.44p)
was used to quantify cell areas. For co-localization studies
of syndecan-2 and caveolin-2, cells were double-stained
with antibodies against syndecan-2 (1:100) and caveolin-2
(1:100), followed by Alexa-conjugated secondary anti-
bodies. Images were acquired using a Zeiss LSM-510 con-
focal microscope (Carl Zeiss) equipped with a diode laser
(405 nm), an argon laser (488 nm) and two helium-neon
lasers (543 nm and 633 nm) and the Zen 2009 software. A63X numerical aperture (NA) 1.4 oil-immersion Plan-
Apochromat objective (Carl Zeiss) was used.
In vitro invasion assay
Invasion assay were performed as previously described
[27]. The membrane on the top chamber (12-well insert;
pore size 8 μm, Millipore, Billerica, MA, USA) was
coated with a mixture of 3 mg/ml acid-soluble type I
collagen (Cellmatrix type 1-A, Nitta Gelatin, Osaka,
Japan) and 10× RPMI medium (Sigma-Aldrich, St Louis,
MO, USA) in a 9:1 ratio. The pH of the collagen mixture
was adjusted to pH 8 with 1 M NaOH on ice. The colla-
gen mixture was further diluted with DMEM medium to
a final concentration of 2 mg/ml and incubated for
30 min at 37°C. Cells were plated on the top chamber in
medium without serum and medium with serum was
placed in lower chamber as a chemoattractant. The cells
were incubated for 24 h and non-invasive cells were re-
moved by cotton swab. The invasive cells were fixed,
stained for DAPI and analysed on a Zeiss Axioplan-2
microscope (Carl Zeiss). Numbers of invaded cells on
each whole membrane were quantified. In further con-
trol experiments, uncoated filters were used in place of
collagen-coated filters.
Collagen degradation assays
Collagen degradation assays were performed according
to [27]. 12-well cell culture plates were coated with a
thin layer of approx. 2.7 mg/ml PureCol™ collagen
(Nutacon, Leimuiden, The Netherlands) containing 10×
RPMI medium (pH 8). Plates were incubated for 1 h at
37°C to form fibrillar collagen. Cells were cultured on
the fibrillar collagen for 48 h then removed by trypsin-
EDTA (Life Technologies). The collagen films were fixed
with 4% paraformaldehyde for 30 min, stained with Coo-
massie Brilliant Blue R250 and analysed on an Axiovert
135 microscope (Carl Zeiss). The clear unstained zones
indicated areas of degraded collagen. Images were quan-
titated using Volocity 6.0.1 software.
Western blotting and co-immunoprecipitation
Cells were lysed in sample buffer containing 62.5 mM
Tris–HCl pH 6.8, 2% sodium dodecyl sulfate (SDS), 10%
glycerol, 5% β-mercaptoethanol, and 0.001% bromophe-
nol blue. For phosphorylated protein detection, cells
were lysed with cold lysis buffer containing 50 mM Tris
pH 7.4, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100,
25 mM NaF, 2 mM NaVO4 and protease inhibitor cock-
tail (Roche, Mannheim, Germany). Cell lysates were re-
solved on 10% SDS-PAGE, proteins were transferred
electrophoretically to PVDF membranes (Bio-Rad, USA)
and blotted with the indicated antibodies. Blots were
quantified using TotalLab TL100 software (Biosystematica,
Devon, UK). For co-immunoprecipitation experiments,
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HEPES pH7.5, 150 mM NaCl, 1% Triton-X100, 2 mM
EDTA, 1 mM phenylmethylsulfonyl fluoride and protease
inhibitor cocktail. The cell lysates were sheared with 25G
needles and left mixing for 1 h at 4°C. The lysates were
centrifuged at 13,000 rpm for 5 min at 4°C and the super-
natants were pre-cleared with protein A agarose beads
(Sigma-Aldrich, St Louis, MO, USA) for 1 h at 4°C. The
pre-cleared lysates were incubated with caveolin-2 anti-
body and rabbit IgG as a control overnight at 4°C and fur-
ther incubated with protein A-agarose beads for 1 h at
4°C. The beads were washed and eluted followed by elec-
trophoresis and immunoblot analysis.
Isolation of detergent-resistant membranes
Two confluent 15 cm dishes of MDA-MB231 cells were
each scraped in 2 ml PBS on ice after 3 washes in ice
cold PBS (divalent cation free). Cells were pelleted at
2°C at 900 rpm for 5 min. Some dishes were untreated,
while others had been heparan sulfate (20 μg/ml) treated
for the final 24 h. The two pellets were each resus-
pended in 0.6 ml ice-cold MNE (25 mM MES pH6.5,
150 mM NaCl, 2 mM EDTA) containing 1% Triton
X-100, protease inhibitors (Roche protease inhibitor
cocktail, pepstatin and 1 mM PMSF). The lysates were
incubated on ice for 15 min and sheared by passage
through a 25G needle 15 times, all on ice. The lysates
were mixed with 0.6 ml ice-cold 80% (w/v) sucrose/
MNE and divided into 2 × 1.4 ml centrifuge tubes. Each
was overlaid with 0.5 ml 30% and 0.25 ml 5% sucrose/
MNE in a precooled Beckman benchtop MAX-XP ultra-
centrifuge TLS-55 swingout rotor (Beckman Coulter,
Fullerton, CA, USA). Centrifugation was carried out at
200,000 × g for 20 h at 2°C. The Triton-soluble fraction
was defined as the bottom 0.2 ml of the 40% sucrose
layer. The detergent-resistant membrane (DRM) fraction
was clearly visible as an opaque ring at the 30-40%
boundary. Each tube was fractionated into 9 × 150 μl
fractions. One set from control and HS treated samples
were heated with 5× sample buffer. Gels were run (10%
SDS-PAGE) at 125 V. Electrotransfer to PVDF mem-
brane was at 75 V for 90 min. The membranes were
blocked in 5% milk/1% heat treated BSA in TBS for 1 h
at RT, then the membranes were incubated with three
antibodies simultaneously. Antibodies against flotillin
were combined with those against caveolin-2 and trans-
ferrin receptor, all at 1 μg/ml in 1% milk/1% BSA/TBST
at 4°C on a rocking platform. In other experiments, both
antibodies against syndecan-2 or syndecan-4 were used
(1:500 dilution). Membranes were washed at least 4 ×
over 30 min with TBST, then incubated at RT for 1 h in
1:2500 each of GAR and GAM-HRP (combined). Wash-
ing 3 × TBST over 30 min, then TBS with no Triton.
Membranes were incubated with EZ-ECL (BiologicalIndustries, Beit Haemek, Israel). Blots were visualized
and photographed in the LAS4010 instrument (GE
Healthcare, Freiburg, Germany).
Immunohistochemistry
Immunostaining was performed on formalin-fixed
paraffin-embedded breast tissue arrays obtained from
USBiomax (Rockville, MD, USA, cat. no. BRC961,
BRC962, BR486 and BRM961). The material included
24 cases of normal, reactive or benign breast tissue, 168
cases of breast cancer, from which 48 were triple negative
cases and another 48 had matching lymph node metasta-
sis or adjacent normal breast tissue. The sections were
deparaffinised with xylene and rehydrated through graded
alcohols into distilled water. Heat induced antigen re-
trieval in 0.01 M citrate buffer, pH 6.0 was performed [28].
The EnVision + System-HRP Labelled Polymer anti-
Rabbit and Liquid DAB + Substrate Chromogen System
(DAKO) were used for the detection. Polyclonal or mono-
clonal rabbit anti-human antibodies were used to detect
syndecan-2 (diluted 1:50; LSBio) and caveolin-2 (diluted
1:50). Slides were counterstained with haematoxylin, dehy-
drated and mounted in permanent mounting medium
(Eukitt quick-hardening mounting medium; Sigma-
Aldrich). Slides were scanned at a 40× magnification
using the NanoZoomer 2.0-HT digital slide scanner
(Hamamatsu Photonics, Hamamatsu, Japan). The immu-
nohistochemical staining was quantified and analysed.
TMA cores which were either lost or fragmented were ex-
cluded from quantification analysis. Intensity and area of
syndecan-2 and caveolin-2 staining were measured using
BioPix iQ, version 2.1.8 (Gothenburg, Sweden) after ex-
cluding blood vessels, fat tissues and necrotic areas. Inten-
sity per area in ln scale was plotted.
Statistical analysis
Data are presented as standard error of mean. All west-
ern blots were quantified using TotalLAB software (Bio-
systematica, Devon, UK) and values are shown as ratio
to controls. Two-tailed paired t-test was used to com-
pare between groups and one-way ANOVA with Tukey’s
post-hoc test was used for comparison of more than two
groups. p < 0.05 was considered significant. All statistical
analysis and graphs were plotted using GraphPad Prism
5 (La Jolla, CA, USA).
Results
Cell invasion and matrix degradation is blocked by
exogenous heparan sulfate or heparin
The malignant breast carcinoma cell line MDA-MB231
was treated with various glycosaminoglycans at low
doses. On planar substrates it was noted that heparan
sulfate and heparin, but not chondroitin sulfate, had a
marked impact on cell morphology. Cell spreading was
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doubled in response to heparan sulfate. The increased
spreading in response to both heparin and heparan sul-
fate was statistically significant (Figure 1A, B). In addition,
the organization of the actin cytoskeleton was also chan-
ged, with abundant microfilament bundles formed in re-
sponse to the glucosaminoglycans (Figure 1A). These
terminated at focal adhesions, detected by paxillin stain-
ing. Such structures are rare in untreated MDA-MB231
cells, which normally have a more rounded morphology
with few microfilament bundles. Chondroitin sulfate in-
duced no change in the actin cytoskeleton. In addition,
cell-cell junctions, normally sparse in untreated cells, were
increased strongly in heparin and heparan sulfate-treated
cultures. In these cells, cadherin-11 (OB-cadherin) is the
most abundant adherens junction adhesion receptor [29].
Staining for the cadherin-11 and p120-catenin showed
extensive junction formation in response to heparan
sulfate or heparin (Figure 1C), the cells showing typical
epithelial characteristics, although further examination
showed no indication of E-cadherin expression at junc-
tions, with or without glycosaminoglycan treatments (not
shown). Once again, chondroitin sulfate had no impact
on adherens junction formation. Heparan sulfate im-
pact on cell spreading was independent of the presence
of serum in the culture medium.
Treatment of MDA-MB231 cells with Y-27632, which
inhibits the Rho kinases ROCK I and II, led to total loss
of microfilament bundles in cells treated with either
heparin or heparan sulfate, consistent with a normal
actomyosin constitution and function (Figure 1D). Con-
sistent with this, heparan sulfate and heparin-treated
cells had higher levels of Thr18/Ser19 phosphorylated
myosin light chain than control or chondroitin sulfate
treated cells (Figure 1E). However, further experiments
showed that the cell spreading seen with heparan sulfate
or heparin was more complex than simply elevated my-
osin light chain phosphorylation. Transfection of control
cells with a cDNA encoding a mutated MLC where
Thr18 and Ser19 were changed to aspartate (as a phos-
phomimetic [30]) led to fine microfilament bundles but
no pronounced spreading (Figure 1F).
Heparin and heparan sulfate treatments markedly re-
duced collagen gel invasion and degradation compared
to untreated controls or equivalent levels of chondroitin
sulfate addition (Figure 1G, H). Since heparin is known
to interact with type I collagen [31], it was important to
establish whether the effects seen resulted from interac-
tions with the matrix, or the cells themselves. In control
experiments, therefore, collagen matrices were pre-
treated with glycosaminoglycans, and then washed be-
fore addition of mammary carcinoma cells. Under these
circumstances, matrix pretreatment did not retard mi-
gration or degradation (not shown), indicating that theeffects of exogenous heparin and heparan sulfate were
cell-mediated.
Inhibition of the thrombin/PAR-1 receptor signalling
pathway
It is known that thrombin is expressed by many malig-
nant cells, including MDA-MB231 cells [32], along with
its receptor, PAR-1. Since heparin inhibits thrombin, it
was possible that the effects of heparinoids on cell adhe-
sion were related to this pathway. To test this, siRNA
treatments were employed to deplete the PAR-1 receptor
(Figure 2A). This led to a similar, but not identical, cellu-
lar phenotype as heparin or heparan sulfate treatment
(Figure 2B). Cell spreading was markedly enhanced, but
with limited formation of microfilament bundles. Spread-
ing was not further enhanced by exposure of PAR-1
siRNA treated cells to heparin or heparan sulfate
(Figure 2C). Control siRNA treated cells did not in-
crease spreading or microfilament bundle formation,
but could be induced to do so by additional heparin or
heparan sulfate treatment (Figure 2B). Close examination
of junction formation, however, showed that PAR-1 deple-
tion led to modest numbers of small focal contacts or
adhesions compared with heparan sulfate treatment.
Adherens junction formation was not as robust either
(Figure 2D). Consistent with the formation of few
microfilament bundles, there was no change in myosin
light chain phosphorylation in response to PAR-1
siRNA treatment (Figure 2E). Nevertheless, PAR-1
siRNA treatment significantly reduced carcinoma cell
collagen gel invasion and degradation to levels similar
to that achieved with heparan sulfate or heparin treat-
ments (Figure 2F, G).
In further control experiments, thrombin was inhibited
by treatment with exogenous antithrombin III (ATIII)
protein, which had the same effects as PAR-1 siRNA treat-
ment (Figure 3A). Spreading was enhanced, but with
modest microfilament bundle formation (Figure 3A, B).
However, collagen gel invasion was reduced only by ap-
proximately 40% by ATIII, although collagen gel deg-
radation was also reduced (Figure 3C, D). Thrombin
does not cleave triple helical native collagen, so we
hypothesised that the influence of PAR-1 siRNA or an-
tithrombin III treatments were indirect, i.e. a result of
enhanced cell spreading and adhesion. To confirm the
role of cell-derived collagenase in collagen invasion and
degradation, MDA-MB231 cells were treated with
GM6001 to block matrix metalloproteinases. This al-
most completely prevented cell invasion and matrix
degradation (Figure 3E, F). Down-regulation of MMP14
by siRNA had the same effects (Figure 3G-I), while
control siRNAs had no influence on cell behavior. In
particular, inhibition of cell invasion of collagen gels
was near total (Figure 3H) and more effective than
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Figure 1 (See legend on next page.)
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Figure 1 Heparinoids promote adhesion and reduced invasive activity. MDA-MB231 cultures were treated with 20 μg/ml heparan sulfate
(HS), chondroitin sulfate (CS), heparin (Hep) or untreated (Ctrl) for 24 h after which cells were fixed and assessed for (A) F-actin (red) to detect
microfilament bundles and paxillin (green) to detect focal adhesions (arrows), (B) spread cell areas (n≥ 50 per condition), (C) adherens junction
(arrows) components cadherin-11 (green) and p120-catenin (red). (D) Sensitivity of microfilament organisation to 30 μM of Rho kinase inhibitor,
Y-27632 added for 30 min before fixation and staining for F-actin, Bars = 25 μm in A, C, D. (E) Representative western blot of diphosphorylated
(Thr18/Ser19) myosin light chain (ppMLC) and total MLC from cells treated with glycosaminoglycans or untreated. Quantitation for ppMLC and
total MLC levels relative to β-tubulin is shown under the blots. Similar results were obtained in three independent experiments. (F) F-actin
organization in cells transfected with cDNAs encoding wild type MLC (pEGFP-MLC), phosphomimetic MLC (pEGFP-MLC Thr18Asp/Ser19Asp) or
control vector (pEGFP). Phalloidin-stained cultures of the same areas are shown in the inserts. Bar, 25 μm. (G) Cells were plated onto type I collagen gel
coated transwells in the presence or absence of glycosaminoglycans. After 24 h, invading cells were fixed, stained with DAPI and counted. (H) Cells
were cultured on native type I collagen coated plates in the presence or absence of glycosaminoglycans for 48 h. After this period, cells were removed
by trypsin and degraded areas were detected as clear zones by Coomassie Blue staining. Images at higher magnification are shown on the lower
panels. Quantification of matrix degradation images is shown. Bar = 100 μm. Error bars = s.e.m. from three independent experiments. **p < 0.01,
***p < 0.001, n.s.: not significant. Significance was tested by one-way ANOVA with Tukey’s post-hoc test.
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and degradation under normal conditions. To assess
whether PAR-1 depletion affected levels of cell surface
MMP14, FACS analysis for the MMP after control or
PAR-1 siRNA was carried out. In no case were levels of
MMP14 altered compared to untreated control cultures
(Figure 3J). Therefore, the impact on the thrombin/PAR-1
system of heparin and heparan sulfate appears to be separ-
able from the role of MMP14. Moreover, heparan sulfate
is an inefficient inhibitor of thrombin compared to
heparin [33]. Given that thrombin inhibition only partially
recapitulated the effects of exogenous heparin or heparan
sulfate, we hypothesized that other pathways were also
affected by the glycosaminoglycans.Hierarchical roles for Syndecans-2 and −4 in carcinoma
cell behaviour
MDA-MB231 cells express three of the four syndecan core
proteins [34], as detected by qRT-PCR (Figure 4A). To de-
termine whether exogenous heparinoids were competing
with these heparan sulfate bearing molecules, each synde-
can was knocked down by siRNA, either singly or in com-
bination. Knockdown was confirmed by qRT-PCR and
FACS analysis (Figure 4A, B). Striking results were ob-
tained by syndecan-2 depletion. MDA-MB231 cells ac-
quired a spread morphology, with increased microfilament
bundles, cadherin-11 containing adherens junctions and
significantly enhanced focal adhesions (Figure 4C-E, H).
Carcinoma cell invasion and degradation of type I collagen
matrices were commensurately inhibited (Figure 4F, G).
This suggested that heparin or heparan sulfate could com-
pete with syndecan-2 to bring about actin cytoskeletal
changes. It was confirmed that siRNA for syndecan-2 had
no influence on mRNA levels for the other syndecans
(Figure 4A). Control experiments with uncoated, rather
than collagen coated transwells showed that cell migration
was not inhibited by syndecan-2 siRNA treatment (not
shown). This suggests that the absence of syndecan-2specifically decreases extracellular matrix-mediated
migration.
No effects on cell adhesion or junction formation
were noted where syndecan-1 or syndecan-4 were de-
pleted on their own. Moreover, no additional effects
were noted where syndecan-1 was depleted in combin-
ation with syndecan-2 knockdown (Figure 4H). How-
ever, double depletion of syndecan-2 and −4 had one
clearly observable effect, a decrease in the size and
number of focal adhesions, compared with syndecan-2
knockdown alone (Figure 4H). These data are consistent
with previously published roles for syndecan-4 in focal
adhesion assembly [35]. As a whole the data suggest
that syndecan-2 in breast carcinoma plays a major regu-
latory role in maintaining the invasive phenotype and
appears to suppress the focal adhesion promoting role
of syndecan-4.
Further experiments examined the impact of heparin and
heparan sulfate on cell surface levels of syndecans-1, −2
and −4 (Figure 5). Over 24 h, FACS analysis revealed that
levels of syndecan-2 reduced to near background, while
levels of syndecan-4 increased. Syndecan-1 levels were un-
changed throughout. These data are consistent with the im-
pact of syndecan-2 siRNA which leads to loss of the
proteoglycan and an effect of syndecan-4 on focal adhesion
assembly, which is enhanced by heparan sulfate treatment
(Figure 1A). At the same time, knockdown of syndecan-2
had no effect on cell surface PAR-1 levels (not shown), indi-
cating that the effect of syndecan-2 on cell adhesion was in-
dependent of PAR-1.
Caveolin-2 regulates invasive phenotype of MDA cells
Little is understood regarding the signalling function of
syndecan-2. Along with other syndecans, it can bind
PDZ domain proteins through its conserved C2 cyto-
plasmic region. However, binding partners for its unique
V region are unknown. There is, however, one report
that syndecan-2 can interact, directly or indirectly, with


















































































































































































Figure 2 Effects of heparinoids partly results from inhibition of thrombin. MDA-MB231 cells were transfected with PAR-1 or control siRNA.
(A) After 48 h, RNAs were extracted and subjected to qRT-PCR analysis to ascertain PAR-1 mRNA expression levels. siCtrl – control siRNA treatment.
(B) PAR-1 depleted and control cells were incubated with glycosaminoglycans for 24 h, fixed and stained for F-actin. (C) Cell spreading induced by
PAR-1 depletion and addition of glycosaminoglycans to PAR-1 depleted cells was quantified, n≥ 50 cells per condition. (D) PAR-1 depleted and control
cells were stained for paxillin, cadherin-11 and p120-catenin. Small focal adhesions are arrowed. (E). Levels of phosphomyosin light chain (ppMLC)
are unchanged by PAR-1 depeletion by siRNA. Total myosin light chain (MLC) and β-tubulin are shown. (F) Quantification of PAR-1 and control siRNA
treated cells that invaded type I collagen gels after 24 h. (G) Images and quantification of type I collagen degradation by control and PAR-1 depleted
cells. Images at higher magnification are shown in the lower panels. Bars = 25 μm in B and D. Bar = 100 μm in G. Error bars = s.e.m. from three
independent experiments. **p < 0.01, ***p < 0.001, n.s.: not significant. Significance was tested by one-way ANOVA with Tukey’s post-hoc test (C) or
two-tailed paired t-test (A, F and G).
Lim et al. Molecular Cancer  (2015) 14:15 Page 8 of 18form a complex with syndecan-2 in MDA-MB231 cells,
which is consistent with the previous study (Figure 6A).
By confocal microscopy, partial colocalization of
syndecan-2 and caveolin-2 was apparent (Figure 6B).
However, caveolin-2 did not associate with syndecan-4.
In addition, caveolin-2 protein level was reduced upon
syndecan-2 depletion (Figure 6C). Therefore, in furtherexperiments, caveolin-1 and −2 were separately reduced
by siRNA treatments. It was confirmed that specific
knockdown of caveolin−2 had no effect on protein levels
of the alternate caveolin (Figure 6D). However, knock-
down of caveolin-1 resulted in approximately 30% re-
duction in caveolin-2. In terms of cell adhesion, the
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Figure 3 (See legend on next page.)
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Figure 3 MDA-MB231 cell collagen gel invasion requires MMP14 and is slowed by antithrombin III treatment. (A) Various concentrations
of antithrombin III (ATIII) were used to treat MDA-MB231 cells for 24 h followed by fixation and staining for F-actin. The representative images
shown were cells treated with 3 μg/ml of ATIII. Bar = 25 μm. (B) Quantification of spread cell areas in response to ATIII treatment, n ≥ 50 cells per
condition. (C-F) Cell invasion after 24 h (C, E) or degradation (D, F) of type I collagen gels after 48 h in the presence or absence of 3 μg/ml
antithrombin III (C, D) or 50 μM MMP inhibitor GM6001 (E, F). Higher magnification images are shown in the lower panels of D and F. Bars =100 μm.
(G) Cell lysates were prepared 48 h after transfection with siRNA targeting MMP14 or control siRNA. Western blotting confirmed the siRNA-mediated
MMP14 depletion in the treated cells. (H, I) MMP14 depleted cells were subjected to type I collagen cell invasion and degradation assays.
Higher magnification images are shown in the lower panel (I). (J) Relative cell surface expression of MMP14 in PAR-1 depleted cells was
assessed by flow cytometry. Error bars = s.e.m. from three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, n.s.; not significant by
two-tailed paired t-test.
Lim et al. Molecular Cancer  (2015) 14:15 Page 10 of 18two proteins. Reductions in caveolin-1 had no impact
on cell spreading or cytoskeletal organization, although
invasion of collagen gels was reduced (Figure 6E, F, J).
Depletion of caveolin-2, however, recapitulated the ef-
fects of adding exogenous heparin or heparan sulfate,
or syndecan-2 depletion. The breast carcinoma cells in-
creased spreading, microfilament bundle and focal ad-
hesion assembly, and increased the extent of cadherin
11-mediated adherens junctions (Figure 6E-G). Con-
comitantly, collagen degradation and invasion were
much reduced (Figure 6J, K).
To investigate whether the formation of microfilament
bundles was Rho kinase dependent, cells after syndecan-
2 or caveolin-2 depletion were treated with the ROCK
inhibitor, Y-27632. Similar to heparan sulfate or heparin
treatment, Y-27632 treatment inhibited microfilament
bundle formation triggered by syndecan-2 or caveolin-2
depletion (Figure 6H). In addition, synedecan-2 or
caveolin-2 depleted cells, but not caveolin-1 depleted
cells, had higher levels of Thr18/Ser19 phosphorylated
myosin light chain compared to controls (Figure 6I).
The data suggest that microfilament bundle formation
observed in the absence of syndecan-2 or caveolin-2 was
Rho kinase-dependent.
Caveolins are involved in endocytic events, and are
key components of caveolae. While caveolin−1 and −2
interact, specific functions of caveolin-2 are recognized.
To explore this further, detergent-resistant membrane
(DRM) preparations were made from MDA-MB231
cells, using published methods [37]. The detection of flo-
tillin, known to be present in these preparations served
as a marker of the DRM pool. Transferrin receptor was
detected as a component known not to associate with
these membrane entities [38], Analysis of the fractions
obtained from sucrose density gradient ultracentrifuga-
tion showed, as expected, that a major pool of flotillin
could be detected in the low density fractions, but also
in other parts of the gradient. Transferrin receptor was
only present in the bottom fractions (Figure 7A).
Caveolin-2 was exclusively present in the low density
DRM pool but was lost from the low density fractions
where the cells were treated for 24 h before lysis with
20 μg/ml heparan sulfate, shown to induce spreading,adhesion and reduced invasive behavior. Therefore, a
key finding is that caveolin-2 was relocated as a mem-
brane component from a triton-resistant (DRM) pool to
a triton-soluble pool in response to heparan sulfate
treatment. At the light microscopic level, however, no
clear change in the distribution of this protein could be
seen under identical treatment conditions (Figure 7B).
Caveolin-1, on the other hand was not exclusive to the
DRM pool in control cells, and not significantly altered
in buoyant density when cells were glucosaminoglycan-
treated (not shown). Syndecan-2 was located in a pool
midway through the gradient and was undetectable in
membrane fractions after heparan sulfate treatment, in-
dicative of decreased abundance. Syndecan-4, on the
other hand, was not reduced, but present in more of
lower fractions after heparan sulfate treatment. These
data are consistent with the FACS analysis (Figure 5),
showing decreased syndecan-2 and increased syndecan-
4 on the cell surface after heparan sulfate treatment,
Syndecan-2 expression is elevated in metastatic breast
tumour
To determine whether syndecan-2 and caveolin-2 ex-
pression correlates with disease and clinical outcome in
breast cancer patients, we performed immunohisto-
chemical analysis of human breast tissue microarrays.
Syndecan-2 was examined in 161 cases while caveolin-2
was examined in 165 cases. Wherever possible, serial
sections were stained for the two proteins. In normal
tissue, cytoplasmic syndecan-2 expression was observed
in myoepithelial cells around the ducts, which also
co-expressed caveolin-2 (Figure 8A), suggesting that
syndecan-2 and caveolin-2 may also cooperate in signal
transduction in vivo. In tumor cells, syndecan-2 staining
was cytoplasmically distributed but we also noted that
some displayed nuclear staining. More importantly,
syndecan-2 and caveolin-2 staining were significantly el-
evated in cancer patient samples compared to normal
tissues regardless of tumor grade (Figure 8B). We also
performed immunohistochemical analysis to compare
expression of these two proteins in a small number of
matching primary breast tumors and lymph nodes from














































































































































































































































Figure 4 (See legend on next page.)
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Figure 4 Syndecan-2 is a regulator of MDA-MB231 cytoskeleton and behaviour. (A) Specific knockdown of mRNA levels after syndecan-1, −2
or −4 siRNA treatments. mRNA was extracted from cells 48 h after transfection with syndecan-1, syndecan-2, syndecan-4 or control siRNAs. Levels of
other syndecan mRNAs were not affected by syndecan-2 knockdown (left). (B) Flow cytometry analysis confirmed loss of cell surface syndecan-2 after
silencing syndecan-2 with siRNA. (C) Syndecan-2 depleted cells were stained for F-actin, which showed extensive microfilament bundle formation.
Bar = 25 μm. (D) Spread cell areas were increased by syndecan-2 depletion, n≥ 50 cells per condition. (E) Cadherin-11 containing adherens junctions
were visible after syndecan-2 depletion. Bar = 25 μm. (F, G) Type I collagen invasion (F) and degradation (G) were reduced in syndecan-2 depleted
cells. Higher magnification images are shown on the lower panels of G. Bar = 100 μm. (H) Cells depleted of each syndecan individually or in
combination, by siRNA treatment were stained for focal adhesions (arrows) with a paxillin antibody. Quantification of focal adhesion (FA) size
and number was done by one-way ANOVA with Tukey’s post-hoc test. Bar = 25 μm. Error bars = s.e.m. from three independent experiments.
***p < 0.001, n.s.; not significant by two-tailed paired t-test.
Lim et al. Molecular Cancer  (2015) 14:15 Page 12 of 18increase in syndecan-2 staining intensity was observed
in lymph nodes compared to primary tumors, suggesting
that syndecan-2 associates with metastasis during the
course of cancer progression (Figure 8C, D). In contrast,
we did not detect significantly increased caveolin-2
staining in lymph nodes compared to primary tumors. A
closer examination of 47 triple negative breast cancer
cases showed a significant correlation in the expression
of syndecan-2 and caveolin-2 (Figure 8E). These data
demonstrated that syndecan-2 together with caveolin-2
are highly expressed in breast cancers and that they can
combine to promote an invasive phenotype in vitro.
Discussion
Heparin and heparan sulfate are frequently used as
exogenous competitors of cell surface proteoglycan-
mediated events. These glycosaminoglycans potently in-
fluenced the behavior and cytoskeletal organization of
the invasive MDA-MB231 cell line, which is triple nega-
tive (i.e. lacking estrogen, progesterone and Her2Neu/
ErbB2 receptors). Their effects appeared to be due to in-
hibition of two major signaling pathways, thrombin in-
teractions with PAR-1 receptor, and that mediated by a
syndecan-2/caveolin-2 pathway.
Thrombin is a serine protease with key roles in the co-



















Figure 5 Heparan sulfate treatment causes loss of syndecan-2 and ga
at 2, 16 and 24 h after treatment with 20 μg/ml heparan sulfate for cell surfac
analysis showed decreased syndecan-2 to near background, while levels of
the treatment.Thrombin signaling is mediated through a family of
small family of G-protein-coupled protease activated re-
ceptors (PARs). Of the four PAR family members, PAR-
1, is the prototypical member and has been identified as
a potent oncogene based on its ability to stimulate focus
formation and induce NIH3T3 cell transformation [40].
In addition to their normal physiological roles in vascu-
lar biology, there is substantial evidence for aberrant ex-
pression of thrombin and PAR-1 in several cancers,
including breast cancer [32,41-43], melanoma [44,45]
and prostate cancer [46,47]. In breast cancer, increased
PAR-1 expression was closely associated with the inva-
sive capacity of primary breast tissue specimens and
breast carcinoma cell lines [32,41,43,48,49], suggesting
PAR-1 has a critical role in tumor progression. We have
demonstrated that heparan sulfate and heparin may in-
hibit PAR-1 activation by inhibiting thrombin, leading to
cell spreading and attenuated invasiveness of MDA-
MB231 cells. However, PAR-1 depletion did not alter the
cell surface expression levels of the major metallopro-
teinase, MMP14, which was confirmed here to be essen-
tial for collagen invasion and degradation.
We also show that a heparan sulfate proteoglycan,
syndecan-2 is a regulator of breast carcinoma invasive-
ness. Cell invasion and degradation of type I collagen
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Figure 6 (See legend on next page.)
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Figure 6 Caveolin-2 interacts with syndecan-2 and regulates cell adhesion in MDA-MB231 cells. (A) Syndecan-2, but not syndecan-4, was
co-immunoprecipitated with caveolin-2 from cell lysates. Co-immunoprecipitation was not affected by ectopic glycosaminoglycan treatment of
the cells (UT; untreated, CS; chondroitin sulfate, HS; heparan sulfate). (B) Confocal laser scanning microscopy and profile of the line scanning
(white arrow on image) confirmed partial co-localization of syndecan-2 (green) and caveolin-2 (red). (C) Caveolin-2 levels were reduced where
syndecan-2 was depleted by siRNA, compared with control siRNA. (D) Western blotting verified the knockdown efficiency of siRNA targeting
caveolin-1 and −2 compared to control siRNA. Downregulation of caveolin-1 reduced the expression of caveolin-2 by around 30%, but knockdown of
caveolin-2 had no impact on caveolin-1 levels. (E) F-actin containing microfilament bundles were abundant after caveolin-2, but not caveolin-1
depletion. Bar = 25 μm. (F) Spread cell areas were measured in caveolin-2 depleted cells and control cells, n ≥ 50 per condition. (G) Adherens
junctions and focal adhesions (arrows) were characteristic of caveolin-2 depleted cells, shown by cadherin-11 and p120-catenin, or paxillin
distributions. Bar = 25 μm. (H) Microfilament bundles formed in response to either syndecan-2 or caveolin-2 knockdown were sensitive to 30 μM Rho
kinase inhibitor, Y-27632. Bar = 25 μm. (I) Diphosphorylated myosin light chain (ppMLC; Thr18/Ser19) was enhanced in both syndecan-2 and
caveolin-2 depleted cells. Densitometry analysis of western blots for ppMLC and total MLC were normalised to β-tubulin. Similar results were
obtained in three independent experiments. (J, K) Caveolin-2 depleted cells had reduced ability to invade or degrade type I collagen gels. Higher
magnification images are shown in the lower panels. Caveolin-1 depletion also reduced collagen gel invasion. Bar = 100 μm. Error bars = s.e.m.
**p < 0.01, ***p < 0.001, n.s.; not significant by two-tailed paired t-test.
Lim et al. Molecular Cancer  (2015) 14:15 Page 14 of 18Furthermore, reduction in cell invasiveness was accom-
panied by changes in actin cytoskeletal organization and
cell-cell adhesion, where cell spreading, microfilament
bundles, focal adhesions, and cadherin-11 containing
adherens junctions were all enhanced. Thus depletion of
syndecan-2 reveals a mechanism by which it controls

























Figure 7 Exogenous heparan sulfate influences subcellular localisatio
were made from MDA-MB231 lysates, some treated with 20 μg/ml heparan
tube and western blotted for flotillin as a marker of DRM pools, transferrin rec
and caveolin-2. The caveolin-2 is almost exclusively in the DRM pool of contro
with heparan sulfate. Syndecan-2 is reduced after heparan sulfate treatment (
treated with 20 μg/ml heparan sulfate (HS) for 24 h before fixation. While the
alteration in the localisation of caveolin-2. Bar = 25 μm.this heparan sulfate treatment was shown by FACS ana-
lysis to lead to specific syndecan-2 loss from the cell sur-
face, while levels of syndecan-4 increased and syndecan-1
was unchanged. Focal adhesion and microfilament bundle
formation in response to loss of syndecan-2 was shown to
depend on the presence of syndecan-4. Very recent work
suggests that this mechanism involves p190ARhoGAP,B
Ctrl HS
n of caveolin-2. (A) Detergent-resistant membrane (DRM) preparations
sulfate for 24 h. Nine fractions were collected from each centrifuge
eptor as a marker of detergent soluble membrane proteins (non-DRM),
l cells, while it is displaced to the non-DRM pool when cells are treated
B) Caveolin-2 staining of untreated (Ctrl) MDA-MB231 cells and cells
HS-treated cells are more spread than control cells, there is no obvious
A B
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Figure 8 Syndecan-2 expression correlates with metastatic status in patient. (A) Normal breast tissues (Normal) and breast cancer patient
tissues (Cancer) from tissue microarrays were stained for syndecan-2 or caveolin-2 on serial sections. Magnified images are shown in lower panels,
bars = 100 μm. (B) Intensity per area for syndecan-2 or caveolin-2 staining was quantified for each core in tissue microarray to compare normal
breast tissue and patient breast tissue of different tumour grades, n = 161 for syndecan-2 and n = 165 for caveolin-2. Bar graph was plotted in ln
scale. (C) Breast tissue from patients diagnosed with Grade II carcinoma and metastatic lymph node tissue from the same patient were stained
for syndecan-2 and caveolin-2. Higher magnification images are shown in lower panels, bars = 100 μm. (D) Quantification data of intensity per
area of syndecan-2 or caveolin-2 staining from (C), n = 26 for syndecan-2 cases and n = 28 for caveolin-2 cases. Bar graph was plotted in ln scale.
Error bars = s.e.m. *p < 0.05, **p < 0.01, ***p < 0.001, n.s.: not significant, tested by one-way ANOVA with Bonferroni post-hoc test. (E) Levels of
syndecan-2 and caveolin-2 staining from serial sections of the 47 triple negative breast carcinoma cases were significantly correlated. r: Spearman’s
correlation coefficient = 0.328, p = 0.024.
Lim et al. Molecular Cancer  (2015) 14:15 Page 15 of 18which associates with syndecan-4 and active β1 integrin at
the cell margins in the absence of syndecan-2 [50]. Rho-
GAP promotes conversion of GTP-Rho to the inactive
GDP-bound form but is inactivated by Src-mediated tyro-
sine phosphorylation. Previous work has demonstrated
the importance of syndecan-4 regulation of p190RhoGAP
distribution [51] and our data correspondingly show that
Rho kinases (ROCKs) and their downstream target, my-
osin light chain, are required for focal adhesion andmicrofilament bundle formation in MDA-MB231 cells
upon heparan sulfate addition or syndecan-2 depletion.
A very recent study illustrated that syndecan-2 deple-
tion in MDA-MB231 derived 1833 cell line with en-
hanced bone tropism led to inhibition of breast tumor
growth and metastasis to bone in a mouse xenograft
model, in part through enhanced apoptosis [52]. No ef-
fects on junctions or actin cytoskeleton were reported in
this study. However, we did not observe changes in
Lim et al. Molecular Cancer  (2015) 14:15 Page 16 of 18growth or cleaved caspase-3 staining after syndecan-2
depletion (data not shown), indicating that the parental
MDA-MB231 cells and MDA-MB231 derived 1833 cells
might signal through different pathways to regulate inva-
sive behaviour. The current data strongly suggest that
syndecan-2 is a tumor promoter by regulating cytoskel-
etal organization and tumorigenic activity in breast can-
cer cells.
In MDA-MB231 cells, syndecan-2 combines with
caveolin-2 to promote an aggressive phenotype. Caveolin
is the major structural component of plasma membrane
microdomains that play numerous pivotal roles in intra-
cellular trafficking and signal transduction [53,54]. The
MDA-MB231 cell line is known to carry a KRas G13D
mutation [55]. Upon oncogenic Ras transformation in
BalbC/3 T3 cells, syndecan-2 has been shown to form a
complex with caveolin-2 [36], which was also shown
here. The interaction of caveolin-2 with syndecan-2 is
specific, since caveolin-2 did not form a complex with
syndecan-4. This interaction and its consequences deserve
further attention. Strikingly, caveolin-2 depletion yielded
the same cell behavior and cytoskeletal organization as
syndecan-2 depletion, with increased cell spreading,
microfilament bundles, larger and more numerous focal
adhesions and diminished type I collagen invasion and
degradation. Unlike caveolin-2, caveolin-1 depletion did
not give rise to an altered phenotype, though cell invasion
was reduced in these cells. Caveolin-1, but not caveolin-2
has been identified as being important for the formation
and activity of invadopodia [56]. Therefore, reduced cell
invasion in caveolin-1 depleted cells may result from
impaired invadopodia function. Caveolin-2, on the
other hand, might stimulate cell invasiveness through
different mechanisms than caveolin-1, which awaits fur-
ther elucidation.
In breast carcinoma, caveolin-2 expression is fre-
quently upregulated and correlates with poor prognostic
status [57,58]. However, there is no previous evidence
for involvement of a syndecan-2/caveolin-2 axis in breast
tumor cell metastasis. Our patient tissue microarray data
showed that syndecan-2 expression and caveolin-2 were
significantly increased in breast cancer patients regardless
of tumor grade. More importantly, syndecan-2 expression
was upregulated in lymph node samples compared dir-
ectly with the primary tumours and in triple negative
cases, expression of syndecan-2 and caveolin-2 were
correlated.
Syndecan-2 has remained very elusive with regard to
its signaling ability. The syndecan-2/caveolin-2 relation-
ship may provide an important insight into regulation of
a specific membrane microdomain in tumour, and per-
haps untransformed cells. Previous work has shown that
syndecan-1 upregulation in breast carcinoma is associ-
ated with poor prognosis, particularly when present inthe stroma [21,59]. Recent data also suggests that
syndecan-2, normally considered a mesenchymal proteo-
glycan, is upregulated and a potential target in colon car-
cinoma [18]. It was also noted as upregulated by gene
expression profiling in breast cancer [60] but insight into
its function has been lacking. Given the importance of
syndecans in breast, colon and other cancers such as mye-
loma [61] their role on the cell surface is increasingly im-
portant to understand. The fact that exogenous heparan
sulfate and heparin inhibit two pathways that support an
invasive phenotype suggests that cell surface proteogly-
cans are a promising area for development of reagents
and understanding of breast carcinoma invasion and
metastasis.
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